|Day Low/High||22.66 / 22.90|
|52 Wk Low/High||22.16 / 31.29|
Data and industry conferences will likely be catalysts for shares in the space.
U.S. equity futures gave back earlier gains Monday even as investor concern over prolonged military action in Syria faded following weekend missile strikes in reaction to an alleged chemicals weapons attack last week in the city of Douma.
Shire will sell its oncology business to France's Servier for around $2.4 billion as it contemplates a possible $50 billion takeover from Japan's Takeda Pharmaceutical Co.
Oil remained near a three-year high despite falling back slightly on Thursday.
China on Friday said it would counter Trump's proposed new tariffs 'to the end, and at any cost'
Wall Street is also expected to start the day in positive territory on Thursday after tumultuous trading on Wednesday.
Strength in the morning yields to weakness in the afternoon session as stocks are sold off Wednesday.
Shire Pharmaceuticals shares hit a year-to-date high Wednesday after Japan's biggest drugmaker, Takeda, confirmed it may make a takeover approach for the U.K.-listed group.
Deal combines Mindstrong's digital phenotyping platform with Takeda's development capabilities
Annual Award Spotlights Takeda's Local Workforce Talent and Commitment to Enhancing Employee Development
Takeda's Commitment to Investing in Deerfield Operations Yields Positive Employee Survey Results
Animal health and oncology deal activity is heating up in 2017.
Shares of Ariad Pharmaceuticals soared Monday after Japan's Takeda Pharmaceutical offered to buy the leukemia drug maker.
The Nikkei 225 closed with a gain for 2016, making a run of five consecutive higher year-end closes -- the first since the 1990 bubble.
The SEC has released correspondence between the agency and Valeant over concerns about its tax accounting and non-GAAP reporting measures.
Here's a technical look on how to trade some of the most active stocks on the market today.
Valeant shares fell Wednesday on news that talks with Takeda to take over Valeant's Salix unit have broken down.
Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.
Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.